There are currently no FDA-approved treatments for FAP, a condition characterized by the proliferation of polyps in the colon and/or rectum.

A clinical-stage biotech company developing first-in-class targeted and immune-mediated therapeutics to fight cancer.

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC ...